Elevance reaffirms FY2025 adjusted EPS guidance of $34.15-$34.85

Elevance Health, Inc.

FY2025 GAAP EPS guidance $28.30-$29.00, including ~$5.85 net unfavorable items.
Adjusted EPS guidance unchanged at $34.15-$34.85.
Benefit expense ratio guidance reaffirmed at 89.1% ± 50 bps.
Company expects 60% of adjusted EPS to be realized in first half of 2025.
Officers reiterate guidance during investor meetings this week.

item 7.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.